A

Avalo Therapeutics

Develops IL-1beta-targeting biologics for inflammation

Head of Global Marketing & Launch Lead - Dermatology

Product MarketingConfirmed live in the last 24 hours
Full-timeChesterbrook, PA, USANo salary listedIn-person

About the Job

Requirements

  • A bachelor's degree is required; an advanced degree such as an MBA, Master of Public Health, Doctor of Pharmacy, Master of Science, or PhD is preferred.
  • At least 12 years of biotechnology, pharmaceutical, or healthcare industry experience.
  • At least 5 years leading launch planning, launch excellence, commercial operations, new product planning, or strategic program management.
  • Demonstrated success leading at least one major pharmaceutical or biotechnology product launch.
  • Experience coordinating complex cross-functional initiatives in a matrixed environment.

Responsibilities

  • Advance and lead the overall commercial strategy for abdakibart, Avalo’s lead drug candidate, in Hidradenitis Suppurativa (HS).
  • Build the brand vision, positioning, messaging, value proposition, and lifecycle strategy.
  • Direct market assessment, forecasting, competitive intelligence, and commercial planning activities.
  • Translate clinical and scientific data into differentiated customer-focused strategies.
  • Identify market opportunities, risks, and competitive dynamics to inform business decisions.
  • Serve as the commercial lead on cross-functional program teams.
  • Manage external agency partners.
  • Build and execute comprehensive cross-functional launch readiness plans.
  • Establish launch milestones, key performance indicators, governance structures, and performance tracking mechanisms.
  • Lead pre-launch customer engagement and market-shaping initiatives.
  • Ensure organizational readiness across marketing, sales, market access, patient services, and operations.
  • Develop launch scenarios and contingency plans to support evolving clinical and regulatory timelines.
  • Generate actionable insights from healthcare providers, patients, payers, advocacy groups, and key opinion leaders.
  • Develop customer segmentation and targeting strategies.
  • Establish strong relationships with external experts, advocacy organizations, and HS stakeholders.
  • Partner closely with Market Access to develop payer, reimbursement, and value communication strategies.
  • Support pricing, contracting, and access planning efforts.
  • Ensure commercial strategies are aligned with payer expectations and patient access objectives.
  • Collaborate closely with Clinical Development and operations, HEOR, Medical Affairs, Regulatory Affairs, Manufacturing, and Supply Chain to ensure commercial perspectives are integrated throughout development.
  • Partner with Medical Affairs to optimize scientific communication plans and publication strategies.
  • Support investor and board communications regarding the commercial opportunity for abdakibart in HS and launch readiness plans.
  • Represent commercial perspectives in governance and strategic planning discussions.

Desired Qualifications

  • Experience in dermatology and/or immunology/inflammation specialty products.
  • Experience launching biologics or specialty therapies.
  • Understanding of HS, dermatology, immunology, or inflammatory disease markets.
  • Experience within emerging biotechnology companies and first-launch organizations.
  • Familiarity with global launch planning and commercialization frameworks.

About the Company

Avalo Therapeutics

Develops IL-1beta-targeting biologics for inflammation

Avalo Therapeutics develops biologic therapies that target the IL-1beta pathway for immune-mediated inflammatory diseases. Its lead candidate, abdakibart (AVTX-009), is a humanized monoclonal antibody that inhibits IL-1beta and blocks downstream inflammatory signaling, advancing toward a registrational Phase 3 program after positive Phase 2 results in hidradenitis suppurativa. AVTX-010 is a long-acting next-generation anti-IL-1beta antibody designed to extend dosing intervals. The company focuses on research and development of novel biologics with commercialization expected through pharmaceutical partnerships and product sales. Unlike some competitors that pursue broader or different inflammatory targets, Avalo concentrates specifically on IL-1beta–related inflammation with a pipeline aimed at improving dosing convenience and clinical outcomes in inflammatory diseases.

Company size
51-200
Company stage
IPO
Headquarters
Rockville, MD
Founded
2011

Recently Posted Jobs

Explore more opportunities at Avalo Therapeutics

See more jobs